Coya Therapeutics, INC 8-K filings

Coya Therapeutics' stockholders approved an amendment to the company's 2021 Equity Incentive Plan, increasing the number of shares available for issuance by 750,000 to a total of 2,571,070.

Coya Therapeutics announced its 2023 financial results and provided a corporate update, highlighting progress in its clinical programs and strategic collaborations.

Coya Therapeutics reports a cash balance of $32.6 million as of December 31, 2023, and received a $7.5 million milestone payment in January 2024, boosting its pro forma cash position to $40.1 million.